0001615774-17-003793.txt : 20170725 0001615774-17-003793.hdr.sgml : 20170725 20170725133820 ACCESSION NUMBER: 0001615774-17-003793 CONFORMED SUBMISSION TYPE: 1-U PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170719 ITEM INFORMATION: Other Events FILED AS OF DATE: 20170725 DATE AS OF CHANGE: 20170725 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Alzamend Neuro, Inc. CENTRAL INDEX KEY: 0001677077 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 811822909 STATE OF INCORPORATION: DE FISCAL YEAR END: 0430 FILING VALUES: FORM TYPE: 1-U SEC ACT: 1933 Act SEC FILE NUMBER: 24R-00058 FILM NUMBER: 17980104 BUSINESS ADDRESS: STREET 1: 50 W. BROADWAY STREET 2: 3RD FLOOR CITY: SALT LAKE CITY STATE: X1 ZIP: 84101 BUSINESS PHONE: 9493465822 MAIL ADDRESS: STREET 1: 50 W. BROADWAY STREET 2: 3RD FLOOR CITY: SALT LAKE CITY STATE: X1 ZIP: 84101 1-U 1 s106899_1u.htm 1-U

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 1-U

 

CURRENT REPORT PURSUANT TO REGULATION A

 

Date of Report: July 19, 2017

(Date of earliest event reported)

 

Alzamend Neuro, Inc.

(Exact name of issuer as specified in its charter)

 

Delaware
(State or other jurisdiction of
Incorporation or Organization)

 

50 W. Broadway, 3rd Fl., Salt Lake City, UT 84101

(Full mailing address of principal executive offices)

 

(949) 346-5822

(Issuer’s telephone number, including area code)

 

Title of each class of securities issued pursuant to Regulation A:

Common Stock, par value 0.0001 per share

 

 

 

  

 
 

 

Item 9. Other Events

 

As of July 19, 2017, our offering made pursuant to our Offering Statement on Form 1-A (the “Offering”), which was qualified by the Securities and Exchange Commission on December 8, 2016, has expired. We held a closing of the Offering on June 15, 2017, when we sold 37,462 shares of common stock at $2.00 per share for aggregate gross proceeds of $74,926.

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of Regulation A, the issuer has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

(Exact name of issuer as specified in its charter) Alzamend Neuro, Inc.

 

By (Signature and Title) /s/ Philip Mansour, CEO

 

Date July 25, 2017